Država: Kanada
Jezik: angleščina
Source: Health Canada
PERINDOPRIL ERBUMINE; INDAPAMIDE
SERVIER CANADA INC
C09BA04
PERINDOPRIL AND DIURETICS
8MG; 2.5MG
TABLET
PERINDOPRIL ERBUMINE 8MG; INDAPAMIDE 2.5MG
ORAL
30/100
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0248401003; AHFS:
APPROVED
2009-01-12
_ _ _COVERSYL_ _®_ _ PLUS LD / COVERSYL_ _®_ _ PLUS / COVERSYL_ _®_ _ PLUS HD _ _(perindopril erbumine / indapamide) Product Monograph _ _Page 1 of 65_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr COVERSYL® PLUS LD Tablets, 2 mg / 0.625 mg Oral Pr COVERSYL® PLUS Tablets, 4 mg / 1.25 mg Oral Pr COVERSYL® PLUS HD Tablets, 8 mg / 2.5 mg Oral perindopril erbumine / indapamide Angiotensin Converting Enzyme Inhibitor / Diuretic Servier Canada Inc. 3224 Avenue Jean-Béraud #270 Laval, Quebec, H7V 2S4 Date of Initial Authorization: October 4, 2002 Date of Revision: October 21, 2022 Submission Control Number: 264225 _ _ _COVERSYL_ _®_ _ PLUS LD / COVERSYL_ _®_ _ PLUS / COVERSYL_ _®_ _ PLUS HD _ _(perindopril erbumine / indapamide) Product Monograph _ _Page 2 of 65_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 10/2022 7 WARNING AND PRECAUTIONS 10/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES................................................ Error! Bookmark not defined. TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics (< 18 years of age).............................................................................. 4 1.2 Geriatrics (> 65 years of age) .............................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Consi Preberite celoten dokument